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Abstract
Natural products have played major roles in drug discovery and provided sources for
many new drugs. Secondary metabolites, also called natural products, are organic compounds
that are produced from fungi, bacteria, and other living organisms. Secondary metabolites
produced by endophytic fungi include alkaloids, phenols, peptides, enzymes, polyketides, and
terpenes. Endophytic fungi are rich sources of secondary metabolites and demonstrate bioactivity
against many human pathogens including the ESKAPE pathogens.
This thesis explores the diverse roles of endophytic fungi and their production of unique
secondary metabolites for potential drug discovery and development. Secondary metabolites
from two endophytic fungi (EG10-21E-2-HDAC & TAP14-34A-2-HDAC), collected from
Mexico and Florida, were isolated and characterized using dereplication and compound isolation
methods. Methods of dereplication using LC-MS/MS applied to the fungi resulted in
identification of known toxins and diverse secondary metabolites using molecular networking.
Isolated compounds were prioritized and characterized using NMR analysis and mass
spectrometry techniques. Fungal identification data of EG10-21E-2 & TAP14-34A-2 were
obtained following DNA extraction, PCR amplification, Sanger sequencing, and phylogenetic
analyses.

ix

1. Marine Natural Products and Endophytic Fungi
1.1. Marine Natural Products
Natural products have long served as a foundation for drug discovery and are the sources
of many drugs produced today. Natural products are characterized by strong pharmacological
and biological activities and possess high structural diversity. Extracts prepared from natural
sources contain structurally diverse compounds called secondary metabolites.1 The biosynthesis
of secondary metabolites (natural products) is important in many biological relationships
between organisms.2
Drug development from natural products is based on the assessment of biological
activities of pure compounds and bioassay-guided fractionation using crude extracts.1 Natural
products can be obtained from four main sources including plants, animals, marine organisms
and microorganisms.1,2 Fungi produce structurally diverse secondary metabolites that may
possess biological activities such as antibiotic, anti-inflammatory, and anticancer activities.3 Only
5% of the world’s fungal species are known.4
The biodiversity in marine ecosystems has resulted in structurally diverse secondary
metabolites produced by various marine microflora and microfauna, where few have been
studied for their bioactivity.5 Marine natural products are a rich source of biologically active
compounds from organisms including tunicates, sponges, and mangroves. Approximately 28,500
marine natural products (MNPs) have been identified and many new MNPs have been isolated.6
According to Figure 1.1,7 fungi represent a small number of marine natural product derived
agents (5%).
1

Figure 1.1 Collected Sources and Predicted Biosynthetic Sources of Marine Derived Drugs.7 A.
Marine Natural Product Derived Agents as Approved Drugs (20 total). B. Marine-Derived Drugs
and Clinical Trial Agent from their Predicted Source Organisms.
Sources of marine natural products including marine microorganisms often have the
distinct ability to produce compounds showing promising bioactivity. The marine environment
has become a promising source for natural products and drugs possessing therapeutic use.8
Deriving drugs from marine sources presents many challenges and limitations for drug
development including supply, toxicity, formulation, and pharmacogenetics.8
1.2 Endophytic Fungi
Endophytic fungi live within a plant without causing disease. The existence of
endophytes has been known for hundreds of years, but recently studies on these organisms and
their bioactivity have begun.9 Bioactive compounds produced by endophytes have proven useful
in human medicine and agriculture.10 Endophytes are found in almost every plant species and
within each plant, at least one or more endophytes is hosted by that plant.11 Endophytes may
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produce host secondary metabolites that possess therapeutic value, examples including
camptothecin and paclitaxel.12,13

Camptothecin

Paclitaxel (Taxol)

Endophytic fungi can produce a wide range of bioactive secondary metabolites showing
unique chemical diversity and biological activities.14,15 Secondary metabolites produced by
endophytic fungi often have antifungal, antibacterial, antimicrobial, and cytotoxic activity.15
Secondary metabolites are divided into four main classes including non-ribosomal peptides,
polyketides, alkaloids and terpenes. The isolation of secondary metabolites from bioactive
endophytic fungi are characterized by different methods.
The diversity and biological activity of endophytic fungi is often characterized by
metabolic processes that produce molecules that protect the microbe and host plants.16 The
biodiversity of endophytic fungi shows promising novel molecular structures and biologically
active compounds.17 Endophytic fungi within individual plant hosts have gained recent interest
in fungal ecology, fungal classification, and pharmaceutical applications.18
Mangroves, host plants that grow in coastal saline or brackish water, are sources for
abundant endophytic fungi. Mangroves are ecosystems rich in biodiversity and produce
endophytic fungi useful for pharmacological and pharmaceutical applications. Bioactive
3

compounds from mangrove endophytic fungi grown in the presence of epigenetic modifiers can
modulate gene expression for the synthesis of secondary metabolites.19 In one study,
approximately 72% of analyzed mangrove endophytic fungi cultured in media containing histone
deacetylase inhibitors (HDAC) and DNA methyltransferase inhibitors (DNMT) produced active
extracts.20 The diversity of endophytic fungi has mainly been studied on barks, branches, leaves
and roots of mangroves to identify biological activity.21 Reported endophytic fungi isolated from
mangroves include Aspergillus, Cladosporium, Penicillium, and Fusarium.21
1.3 Drug Discovery of Endophytic Fungal Natural Products
The abundance of natural compounds present in mangroves is reflected by the rich
biodiversity of these environments.22 Medicinal plants and their endophytes are important
sources of bioactive compounds and secondary metabolites, which contribute more than 80% of
natural drugs available.23 The discovery of novel antimicrobial secondary metabolites and
bioactive compounds derived from endophytic fungi have been an important alternative to
combating the increase in drug resistance among various pathogenic microorganisms.23
Endophytic fungi are valuable sources of natural biologically active compounds with a variety of
medicinal, pharmaceutical, and pharmacological applications. With endophytic fungi present in
almost every marine organism, fungal endosymbionts represent significant fungal biodiversity
impacted by host community diversity, structure, and location.23 Marine endophytic fungi
provide important sources for secondary metabolites, which are useful for drug discovery.
Several hits from lead compounds have been obtained from marine endophytic fungi yielding a
wide range of antibacterial and anticancer properties in organisms.24
The biosynthesis of secondary metabolites produced by endophytic fungi is dependent
upon ecological, biological, and physical factors and can result in the production of new
4

metabolites.25 Fungal natural products produced by endophytic fungi play a significant role in the
drug discovery and development process in which they provide a source of diverse secondary
metabolites needed to produce biologically active compounds. Marine endophytic fungi
primarily contain alkaloids and terpenoids as their bioactive compounds.26 These secondary
metabolites produced by endophytic fungi show different biological activities, which include
antimicrobial and antifungal activities against different marine microbe and fungal isolates.
Marine natural products have been important in the development of therapeutics for infectious
diseases and sources of new and approved drugs. Figure 1.2 shows sources of new and approved
drugs for treatment of human disease that have been reported as natural products for leads to
potential drugs.27 Figure 1.2 also shows the codes used in analyses of new and approved drugs
and their percentages including: B (biological macromolecule), N (unaltered natural product),
NB (botanical drug), ND (natural product derivative), S (synthetic drug), V (vaccine), and /NM
(mimic of natural product). Marine endophytic fungi have also provided sources for diverse
antibacterial compounds in response to a need for development and discovery of new classes of
antibacterial compounds showing potential as anti-infective agents.28

5

Figure 1.2. New approved drugs, 1981-2014.27

Drug discovery from marine natural products has resulted in the production of numerous
bioactive compounds and high screening rates for drug leads.29 Marine endophytic fungal natural
products have contributed many biologically active compounds due to their biodiversity and
chemical diversity. From a National Cancer Institute preclinical cytotoxicity screening,
approximately 1% of tested marine organisms showed anti-tumor potential versus 10% of
terrestrial organisms.30 Marine natural products with bioactivity show strong efficacy as drugs
and therapeutics for discovery and development. Advances in sampling techniques, structure
determination, and target identification of marine natural products and bioactive secondary
metabolites have successfully resulted in the discovery of new marine-derived drugs.
The development of promising compounds and hopeful drug candidates derived from
marine endophytic fungi and their biologically active compounds will lead to a wave of new
marine drugs that can be useful in the drug market and in pharmacies worldwide. Secondary
6

metabolites produced from marine endophytic fungi have been reported to have potential to be
developed as new drugs, with several serving as anticancer compounds, showing promising
bioactivity against different drug targets.31 Examples of compounds useful for drug discovery
and development include spirobrocazine C and brocazine G were obtained from Penicillium
brocae, a marine endophytic fungus, and their chemical structures were determined using NMR
and mass spectrometry techniques.32 Spirobrocazine C is a diketopiperazine alkaloid with a
spirocyclic skeleton isolated and characterized from the mangrove-derived Penicillium brocae
which shows strong bioactivity against cancer targets.33

Brocazine G

Spirobrocazine C

For future developments in drug discovery, marine endophytic fungal natural products
provide a promising source of pharmaceuticals with up to 51% of bioactive metabolites isolated
from endophytic fungi collected from mangroves due to recent advances in biotechnology.33
Current challenges in research involving marine endophytic fungi to produce secondary
metabolites with biologically active compounds from cultures has sparked interest in many
microbiologists, environmental biologists, and marine chemists in producing compounds deemed
useful for drug discovery and potential biotechnological applications in the future.
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1.4 The ESKAPE Pathogens
The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, and Enterobacter spp.) are
responsible for approximately two-thirds of all hospital-borne infections according to the Center
for Disease and Control.34 According to the World Health Organization, the ESKAPE pathogens
are currently listed among 12 other problematic bacteria due to antibiotic resistance.35 The
ESKAPE pathogens are also responsible for many nosocomial infections and can escape the
biocidal action of antimicrobial agents.36 The ESKAPE pathogens include both Gram-negative
and Gram-positive bacteria.
ESKAPE pathogens contribute to the need for new antibiotics to treat human infections.
Multidrug resistance observed in the ESKAPE pathogens are grouped according to drug
inactivation, modification of an antibiotic target binding site, and reduced accumulation of the
drug.36 The ESKAPE pathogens are also able to form biofilms, a collection of cells coated in an
extracellular matrix composed of polysaccharides, DNA and proteins.37 Biofilms protect
persister cells that are tolerant to antibiotics and prevent the immune responses of host cells and
antibiotics in inhibiting pathogens.37,38 Biofilm matrices can provide biochemical shields that
provide conditions needed for drug activity and antibiotic resistance including water availability,
pH, O2 and CO2 levels.37 The antimicrobial activity of secondary metabolites obtained from
endophytic fungi can be tested for inhibition against the ESKAPE pathogens.
Enterococcus faecium, a Gram-positive ESKAPE pathogen, is normally found in the gut
of humans and other animals and is the most clinically relevant due to the number of growing
hospital infections across the United States.39 Staphylococcus aureus, a Gram-positive ESKAPE
pathogen, is normally found on the skin or in the nose of healthy individuals. Many endophytic
8

fungi and their novel bioactive secondary metabolites show strong antimicrobial activity against
multidrug resistant S. aureus. Methicillin-resistant Staphylococcus aureus (MRSA), one of the
fastest growing and evolving pathogens, has presented a problem to many developing countries
causing high mortality rates.40
Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and
Enterobacter spp. are Gram-negative ESKAPE pathogens responsible for an increase in
antimicrobial infections worldwide.42 Production of secondary metabolites that function as
antimicrobial agents against the ESKAPE pathogens are useful in developing antibiotics to treat
these infections. Plant secondary metabolites possess distinctive chemical structures and
properties that affect the inhibition of the ESKAPE pathogens and other pathogens that cause
human infection. Targeting the ESKAPE pathogens with secondary metabolites isolated from
marine endophytic fungi may provide scientists opportunities to develop antimicrobial drugs
useful in treating human infection.
1.5 Conclusion
Many studies of marine endophytic fungi and their secondary metabolites have shown
promising bioactivity against pathogens including the ESKAPE pathogens. Marine endophytic
fungi are excellent producers of secondary metabolites, which are useful in antimicrobial drug
development. The biodiversity and chemical entities of mangrove endophytic fungi have resulted
in the production of many biologically active compounds that could potentially target bacteria,
cancer, and viral pathogens. Endophytic microbes from mangroves live in marine ecosystems
with high salinity which makes them a useful source for discovery of secondary metabolites.43
The discovery of potentially promising bioactive compounds derived from mangrove endophytic
fungal natural products may lead to the development of numerous drug candidates and novel
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therapeutic agents, which could prompt researchers to generate new classes of marine drugs for
the pharmaceutical market.
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2. Isolation and Structural Analysis of Natural Products from Endophytic Fungi
2.1 Research Objective
Endophytic fungi from mangrove roots, stems, leaves, and bark were collected from
different years and sampling locations by previous Baker lab members. This project focuses on
endophytic fungi collected in 2010 and 2014 from the Everglades, Florida and Tapachula,
Mexico. The endophytic fungi EG10-21E-2 and TAP14-34A-2 were studied through extraction,
isolation, and identification methods. NMR analysis and bioassay-guided fractionation were used
to determine the potential of the endophytic fungi to produce new secondary metabolites and
biologically active compounds for future natural product drug discovery.
2.2 Scale Up of EG10-21E-2 & TAP14-34A-2
EG10-21E-2 and TAP14-34A-2 were grown on Sabourad dextrose agar (SDA) plates
from glycerol stocks contained in an -80°C freezer. After a colony was formed, 1 mm x 1mm
fungal plugs were placed into FalconTM tubes containing 50 mL of SDB media. Falcon tubes
containing the fungal plugs were incubated at 32°C before adding to rice media. Epigenetic
modifier histone deacetylase (HDAC) was added to an additional Falcon tube using 2.2 mg of
sodium butyrate prepared with 50 mL of Sabourad dextrose broth (SBD) media. The HDAC
inhibitor was added to the SDB media followed by the addition of 300 g of rice, 500 mL of
deionized water into Unicorn bags, and then autoclaved using a liquid cycle for 30 minutes at
121°C. Once the Falcon tubes were incubated, the fungal material was poured into the
autoclaved rice media and grown on a shelf for 21 days. Following the 21-day growth period on
a shelf, the fungal material was transferred to a 4-liter beaker and extracted overnight using a 1:3
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solution of MeOH: EtOAc, followed by two days using 100% EtOAc. Fungal extracts were
filtered into round-bottom flasks and dried using the Buchi rotavapor apparatus and concentrated
for compound isolation.
2.3 Metabolomic Analysis and Dereplication of EG10-21E-2 & TAP14-34A-2 Natural
Products
Fungal metabolite dereplication strategies involve the analysis of a crude extract for
known secondary metabolites. Extracts containing previously known metabolites having
biological activity are subjected to LC-MS and LC-MS/MS dereplication. Dereplication methods
based on LC-MS and LC-MS/MS are very sensitive and provide high resolution mass
spectrometry data for structural analysis and interpretation using scientific databases.1
Dereplication provides rapid identification of known metabolites using small quantities of crude
extracts and avoids time-consuming isolation procedures.2 GNPS (Global Natural Products
Social Molecular Networking) was used to convert and analyze mass spectrometry data by
searching libraries for known secondary metabolites, nuisance compounds, and toxins that may
be present within an extract. Libraries of extracts were then compared using the Cytoscape
spectral visualization network database found within GNPS.
Dereplication techniques have increasingly improved the workflow for discovery of
natural products by first identifying nuisance compounds and toxins and then having them
removed using chromatographic editing. Once extracts were fractionated, MPLC fractions were
dereplicated using the LCMS-QTOF with electro-spray ionization (ESI) to generate
chromatograms and mass spectra using the Agilent Mass Hunter Qualitative Analysis software
for compound identification. Several known toxins and secondary metabolites were identified
from EG10-21E-2 and TAP14-34A-2 using GNPS.
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Metabolomics, the identification, and quantification of small molecules is useful for
identifying and sourcing novel bioactive compounds. Mass-spectrometry based metabolomics
provides many advantages in analysis of bioactive natural products such as sensitivity and small
sample volume which are beneficial to structural elucidation and comparison against library
databases.3,4 The metabolomic analysis of endophytic fungi and natural products helps to bypass
the isolation step to directly identify known bioactive compounds using computational tools.5
Following dereplication and metabolomic analyses, extracts were subjected to compound
isolation using high performance liquid chromatography (HPLC) to identify new bioactive
natural products. HPLC is the most used technique for purification of extracts and allows for the
analysis of different metabolites to isolate compounds.6 Normal phase HPLC was used to isolate
compounds from EG10-21E-2 & TAP14-34A-2 having potential for characterization of new
secondary metabolites.
2.4 Isolation and Characterization of Natural Products from EG10-21E-2
2.4.1 Collection, Extraction and Isolation of EG10-21E-2
EG10-21E-2 was collected in the Everglades, Florida, during 2010 at N25°49.904’
W081°27.657’ from a red mangrove stem. The fungus was isolated and stored in a glycerol stock
in a -80°C freezer. EG10-21E-2 was subjected to extraction in 1:3 MeOH: EtOAc followed by
two periods of 100% EtOAc. After fully extracting and drying, a partition of the culture was
performed to remove fatty acids from the extract. The EtOAc layer (polar) was prepared for
normal phase MPLC by loading onto a silica gel column. The polar EtOAc layer of the EG1021E-2 sample was loaded onto a silica gel column and subjected to normal phase MPLC
equipped with ELS and a UV detector using a gradient of ethyl acetate and hexanes (Figure 2.1).
Extraction Scheme 2.1 shows the masses of collected MPLC and HPLC fractions following
extractions and partitions.
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Figure 2.1 EG10-21E-2 NP MPLC Chromatogram
EG10- 21E - 2
Extraction MeOH: EtOAc (1:3) and EtOAc
EG10- 21E-2
Crude Extract
5.3 g

Partition Hexane and 7:3
MeOH/H2O

EG10-21E-2EtOAc
1.74 g

EG10-21E-2Hexane
1.1 g

EG10-21E-2- 7:3
MeOH/H2O
1.2 g

Partition
EtOAc/H2O

EG10-21E-2- H2O
1.2 g

MPLC-NP Silica_Hex -> EtOAc

Fraction-A
35.3 mg

Fraction-B
280.4 mg

Fraction-C
120.2 mg

Fraction-D
96.1 mg

Fraction-E
132.5 mg

Fraction-F
146.2 mg

Fraction-G
148.5 mg

Fraction-H
104.1 mg

Fraction-I
46.4 mg

Fraction-J
331.2 mg

HPLC-NP Silica_Hex-> EtOAc

Fraction C-2
5.4 mg

Fraction C-3

Fraction C-4

2 mg

4 mg

Fraction C-5
3.4 mg

Scheme 2.1. Extraction Scheme for EG10-21E-2
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Fraction C-6
2.6 mg

Fraction C-7
3.8 mg

Fraction C-8
3.9 mg

Ten fractions were collected over time for a period of 60 minutes and later analyzed using NMR
spectroscopy. MPLC fractions were prepared for bioactivity screening against the ESKAPE
pathogens and Candida albicans. Bioactive MPLC fractions were further analyzed using NMR
spectroscopy and dereplication techniques for prioritization. Fraction C showed strong
bioactivity against Candida albicans strains ATCC18804 and MYA2876. Fraction C was then
subjected to normal phase HPLC to yield seven fractions for chemical analysis. Fraction 4 (see
appendix A for NMR spectra) was purified following normal phase HPLC indicating a pure
compound and was used to determine the structure of EG10-21E-2-C4 (SPT1). From NMR
analysis, SPT1 was further analyzed for structure characterization.
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2.4.2. Characterization of EG10-21E-2-C-4 (SPT1)

EG10-21E-2-C-4 (SPT1)
In the 1H NMR spectrum of EG10-21E-2-C-4, C28H39NO2, chemical shifts around 7 ppm
indicate the presence of an aromatic system. The number of indole diterpenes that have been
identified continues to increase.7 The region of 7-8 ppm in the 1H NMR spectrum indicated the
presence of aromatic indole protons which included two doublets, two triplets and one singlet [δH
7.53 (1H, d), δH 7.92 (1H, s), δH 7.35 (1H, d), δH 7.19 (1H, t), δH 7.12 (1H, t)]. According to the
1

H NMR spectrum, four methyl protons were also observed [δH 1.48 (3H, s), δH 1.33 (3H, d), δH

1.14 (3H, s), and δH 0.80 (3H, d)]. A comparison of COSY, HSQC, HMBC NMR experiments
and HRESIMS data with an exact mass of 422.3051 obtained using LC-MS confirmed the
assignments for the identification of the compound as cladosporine A, an indole diterpenoid
alkaloid previously isolated from an extract of fungal strain Cladosporium sp.8 The normal phase
HPLC chromatogram (see appendix A for chromatogram) resulted in good separation and
isolation of the compound [SPT 1] yielding a pure compound. Table 2.1 shows a comparison of
1

H and 13C NMR data between SPT1 and cladosporine A.
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Table 2.1. 1D NMR Data for EG10-21E-2-C-4 (SPT1) and cladosporine A8 in CDCl3
Position
1

δca, mult., SPT1
-

δHa, mult., SPT1

δcb, mult., cladosporine A δHb, mult., cladosporine A

7.92 (1H, s)
7.10 (1H, s)

-

2

123.2, CH

3

115.8, C

-

116.0, C

-

4

127.4, C

-

127.6, C

-

5

118.1, CH

7.53 (1H, d)

117.9, C

7.53 (1H, d)

6

119.0, CH

7.12 (1H, t)

119.0, CH

7.11 (1H, t)

7

121.4, CH

7.19 (1H, t)

121.6, CH

7.17 (1H, t)

8

110.9, CH

7.35 (1H, d)

111.1, CH

7.35 (1H, d)

9

135.5, C

-

135.7, C

10

34.6, CH

3.69 (2H, dd)

34.8, CH

3.69 (2H, dd)

11

37.8, CH

2.74 (3H, t)

38.0, CH

2.74 (3H, t)

12

29.1, CH

1.33 (3H, m)

29.3, CH

1.36 (3H, m)

13

28.3, CH2

1.63 (1H, d)

28.5, CH2

1.66 (1H, d)

14

29.6, CH2

2.15, (3H, t)

29.9, CH2

2.15 (3H, t)

15

39.3, C

16

32.2, CH

2.16 (3H, m)

32.2, CH

2.17 (3H, m)

17

24.7, CH2

1.76 (1H, m)

24.9, CH2

1.76 (1H, m)

18

31.4, CH2

2.31 (1H, m)

31.5, CH2

2.30 (1H, m)

19

68.3, CH

4.76 (3H, t)

68.5, CH

4.75 (3H, t)

20

46.7, C

21

71.5, CH

4.75 (3H, t)

71.7, CH

4.74 (3H, t)

22

38.0, CH2

2.34 (1H, m)

38.0, CH2

2.31 (1H, m)

23

39.5, CH

3.37 (3H, t)

39.5, CH

3.40 (3H, t)

24

150.0, C

149.8, C

-

25

110.9, CH2

4.88 (1H, s)

111.4, CH2

4.87 (1H, s)

26

17.9, CH3

1.48 (3H, s)

18.1, CH3

1.47 (3H, s)

27

19.4, CH3

1.33 (3H, d)

19.2, CH3

1.32 (3H, d)

28

15.7, CH3

0.80 (3H, d)

15.9, CH3

0.80 (3H, d)

29

17.7, CH3

1.14 (3H, s)

17.9, CH3

1.13 (3H, s)

-

123.4, CH

7.92 (1H, s)

39.3, C

-

46.9, C

-

a1

7.10 (1H, s)

-

-

-

H NMR spectrum recorded at 600 MHz and 13C NMR spectrum recorded at 150 MHz; b 1H
NMR spectrum recorded at 300 MHz and 13C NMR spectrum at 75 MHz
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2.5 Isolation and Characterization of Natural Products from TAP14-34A-2
2.5.1 Collection, Extraction and Isolation of TAP14-34A-2
TAP14-34A-2 was collected from Tapachula Mexico in 2014 from 15° 7.989N 92°
6.544° W. The endophytic fungus was isolated from a red mangrove branch and then stored
using a glycerol stock in a -80°C freezer. TAP14 was scaled up in rice media and then extracted
using 1:3 MeOH: EtOAc followed by 100% EtOAc over the course of three days. Once fully
extracted, the extract was partitioned using 70% MeOH: Hex to remove any non-polar
components, also known as the defatting step. Following defatting, the extract was partitioned
using ethyl acetate and DI water to give the polar EtOAc layer necessary for normal phase
MPLC shown in Figure 2.2. The EtOAc layer was applied to a silica gel column for normal
phase MPLC using hexanes and ethyl acetate. From the ten collected MPLC fractions, fraction D
showed strong bioactivity against ESKAPE pathogens E. faecium and S. aureus and was further
analyzed using NMR spectroscopy. Fraction D was then subjected to normal phase HPLC (see
appendix A for NP HPLC chromatogram) for compound isolation yielding 3 fractions as shown
in Extraction Scheme 2.2.

Figure 2.2 TAP14-34A-2 NP MPLC Chromatogram
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TAP14-34A-2
Extraction MeOH: EtOAc (1:3) and EtOAc

Partition Hexane and 7:3
MeOH/H2O

TAP14-34A-2
7:3 MeOH/H2O
1.4 g

TAP14-34A-2
Crude Extract
8.1g

Partition
EtOAc/H2O

TAP14-34A-2EtOAc
3.0 g

TAP14-34A-2
Hexane
1.5 g

TAP14-34A-2H2O
0.4 g

MPLC-NP Silica_Hex -> EtOAc

Fraction-A
552 mg

Fraction-B
146.4 mg

Fraction-C
132.9 mg

Fraction-D
80.1 mg

Fraction-E
87.3 mg

Fraction-F
80.4 mg

HPLC-NP Silica_Hex-> EtOAc

Fraction D-1
1.2 mg

Fraction D-2

Fraction D-3

8.4mg

10.8mg

Scheme 2.2 Extraction Scheme for TAP14-34A-2
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Fraction-G
43.8 mg

Fraction-H
11 mg

Fraction-I
8.7 mg

Fraction-J
24.5 mg

2.5.2 Characterization of TAP14-34A-2-D-1 (SPT2)

TAP14-34A-2-D-1 (SPT2)
TAP14-34A-2-D-1 was isolated as a yellowish oil with molecular formula C21H23O5Cl
determined by HRESIMS. The molecular weight of the compound was determined to be 390
amu and the chemical formula was analyzed using LC-MS. ESI MS: 391.1329 [M+H]+; 413.1
[M+Na]+. The isolated compound was first verified using SMARTNMR followed by NMR and
LC-MS analyses.9 According to the 1H NMR spectrum, there is an aromatic proton at 7.94 ppm.
Proton signals between 5-7 ppm were indicative of two alkenes present on H-9 and H-12. A set
of 2D NMR experiments including COSY, HSQC, HMBC, and 13C NMR spectra were acquired
for structural characterization of TAP14-34A-2-D-1 (see appendix A for NMR data). The
HMBC experiment indicated the presence of three ketones (δc 191.7 ppm, δc 192.4 ppm, δc
206.99 ppm). Stereochemistry for SPT2 was confirmed using a NOESY spectrum showing
through-space interactions within the compound on C-16 and C-18. Sclerotiorin was previously
isolated from a strain of Aspergillus terreus and Penicillium frequentans.10,11 Compared to
literature and previous NMR data, the isolated compound was confirmed to be sclerotiorin which
was first isolated in 1940 from Penicillium sclerotiorin.12
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Table 2.2 1D NMR Data for TAP14-34A-2-D-1 (SPT2) and sclerotiorin in CDCl312
δca, mult., SPT2

δHa, mult., SPT2

1

153.4, CH

7.94 (1H, s)

2

157.9, CH

3

114.5, CH

7.76 (1H, d)

114.2, CH

7.68 (1H, s)

4

106.4, CH

6.66 (1H, d)

107.0, CH

6.60 (1H, d)

5

139.2, CH3

1.26 (3H, s)

139.3, CH3

1.34 (3H, s)

6

192.4, CH

7

85.3, CH

8

186.8, CH

9

115.9, C

6.08 (1H, d)

116.3, C

6.08 (1H, d)

10

142.9, CH

7.07 (1H, s)

143.5, CH

7.06 (1H, s)

11

131.9, CH2

1.67 (2H, s)

132.6, CH2

1.68 (2H, s)

12

148.8, C

5.71 (1H, d)

149.5, C

5.71 (1H, d)

13

35.2, CH3

2.49 (1H, m)

35.8, CH3

2.49 (1H, m)

14

30.2, CH2

1.33 (1H, m)

30.7, CH2

1.34 (1H, m)

15

11.7, CH3

0.88 (3H, t)

12.6, CH3

0.87 (3H, t)

16

20.2, CH2

1.01 (3H, s)

20.8, CH2

1.01 (3H, s)

17

12.5, C

1.86 (3H, s)

13.0. C

1.85 (3H, s)

18

23.5, CH3

1.57 (3H, s)

23.2, CH3

1.57 (3H, s)

19

170.6, C

20

19.9, CH3

Position

δcb, mult., sclerotiorin
153.3, CH

-

158.8, CH

-

192.4, CH

7.44 (1H, s)
-

-

-

7.44 (1H, s)

186.6, CH

-

20.7, CH3

a1

7.94 (1H, s)

85.2, CH

170.7, C

2.18 (3H, s)

δHb, mult., sclerotiorin

2.17 (3H, s)

H and 13C NMR spectra recorded at 600 MHz and 150 MHz respectively; b 1H and 13C NMR
spectra recorded at 500 MHz and 125 MHz respectively
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2.6 Summary and Conclusions
The extraction and isolation of endophytic fungal natural products provides many
opportunities for the discovery of new promising bioactive compounds. From EG10-21E-2 and
TAP14-34A-2, two known natural products were successfully isolated, cladosporine A and
sclerotiorin. The two isolated compounds were characterized and determined using 1D and 2D
NMR spectroscopy and HRESIMS. The isolation, structural elucidation, and antimicrobial
activities of cladosporine A and sclerotiorin are presented following an extensive chemical
investigation of the extracted endophytic fungi. Cladosporine A, isolated from EG10-21E-2-C-4
(SPT1), is the first indole diterpenoid alkaloid extracted from fungi Cladosporium.8 SPT1, an
indole diterpenoid alkaloid, is a structurally diverse natural product possessing various biological
and antimicrobial activities.
Sclerotiorin, isolated from TAP14-34A-2-D-1 (SPT2), is a bioactive polyketide isolated
from Penicillium belonging to the azaphilone class of compounds.13 Sclerotiorin and other
structurally similar compounds isolated from Penicillium have biological properties such as
aldose reductase inhibition and function as a reversible lipoxygenase inhibitor.10 The bioactivities
and antimicrobial activities of the isolated compounds show potential for therapeutic applications
and drug development. From the endophytic fungi, many new compounds may be further
investigated from additional bioactive MPLC fractions including EG10-21E-2-G and TAP1434A-2-E and F for the discovery of new novel bioactive natural products.
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3. Fungal Identification of EG10-21E-2 & TAP14-34A-2
3.1 Significance of Molecular Identification of Endophytic Fungi
Fungal identification methods use molecular data from the internal transcribed spacer
(ITS) region to identify fungi, which is the official DNA barcoding marker for species
identification of fungi.1 For fungal identification, the ITS region is the most useful and fastest
barcoding marker due to its large barcode gap and widespread amplification of DNA.2 However,
the ITS region may not work well in some taxa including Aspergillus, Cladosporium, Fusarium,
and Penicillium because there are no barcode gaps in the ITS region.2 Primers for the
amplification of the ITS region are used for the identification of single taxa and environmental
DNA barcoding including endophytic fungi according to Figure 3.1.3 Identification of
endophytic fungi containing novel bioactive secondary metabolites will prove useful for future
applications involving drug discovery.

Figure 3.1 Primers used for amplification of the ITS region.3
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3.2 Research Objective
The molecular identification of endophytic fungi EG10-21E-2 and TAP14-34A-2 was
conducted using genomic DNA extractions, PCR amplification, gel electrophoresis, and PCR
purification. Endophytic fungi grown on SDA plates were extracted for genomic DNA necessary
for molecular identification. Extracted genomic DNA for EG10-21E-2 and TAP14-34A-2 was
used for PCR amplification using the ITS region having one forward and one reverse primer.
Protocols for PCR amplification were established based on the Master Mix and ITS primer
specifications with an initial denaturation (95°C for 2 min), denaturation (95°C for 1 min),
annealing (52°C for 30s), extension (72°C for 1 min), final extension (72°C for 8 min), and hold
(4°C indefinitely). Denaturation, annealing and extension steps were performed for a total of 35
cycles to fully amplify DNA in the ITS region and remove any nucleotide bases from the DNA.
Amplified PCR products were validated using gel electrophoresis to make sure the proper size
DNA band (~600 bp) was produced. Verification of gel electrophoresis using UV-visualization
of DNA enabled purification of PCR products before submitting for Sanger sequencing to
GeneWiz. Sanger sequencing results were then used for identification of the endophytic fungi
using NCBI BLAST and phylogenetic analyses.
3.3 Molecular Identification Studies of EG10-21E-2 & TAP14-34A-2
EG10-21E-2 and TAP14-34A-2, endophytic fungi whose secondary metabolites were
isolated and characterized from NMR analyses, were extracted for molecular identification.
EG10-21E-2 and TAP14-34A-2 were grown on an SDA plate and transferred to a 50-mL
FalconTM tube followed by incubation at 32°C. Biomass from EG10-21E-2 and TAP14-34A-2
was collected into a 2 mL tissue disruption tube with ~0.5 cm of 0.1 mm glass beads. 600 µL of
Tris-EDTA (TE) buffer was added to the biomass and placed into a bead beater for 2 minutes
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followed by centrifuging at full speed for 3 minutes. The supernatant was transferred to a clean
1.5 mL collection tube and 200 µL of 1.6% sarkosyl along with 5 µL of proteinase K to denature
proteins within the endophytic fungi.
EG10 and TAP 14 were incubated at 60°C for three hours followed by addition of 600
µL of phenol chloroform and then centrifuged at full speed for 5 minutes. The aqueous layer of
the sample was transferred to a new clean 1.5 mL collection tube, 500 µL of 100% isopropyl
alcohol + 100 µL of 3M aqueous sodium acetate were added, followed by incubation at -80°C
for 30 minutes and centrifuging at full speed for 10 minutes. The supernatant was removed by
avoiding the small pellet that formed within the collection tube, 500 µL of 70% aqueous ethanol
was added, and then centrifuged at full speed for 5 minutes. The supernatant was removed once
again, and the sample was left to air dry for 4 minutes with the lid of the collection tube open at
room temperature. The EG10 and TAP14 samples were resuspended in 200 µL of DNase free
water by pipetting up and down and then placed into a 4°C media refrigerator.
A quality check for solvent contamination and purity of DNA was conducted using the
ThermoScientific Nanodrop Spectrophotometer (see appendix B for Nanodrop curve) to move
forward with PCR amplification. An optimal purity range for extracted genomic DNA is ~1.82.0. For EG10, the 260/280 reading was recorded at 1.63, 260/230 was 2.05 and the
concentration of the DNA was 67.2 ng/µL. For TAP14, the 260/280 reading was recorded at
2.01, 260/230 at 2.06 and the concentration of the DNA was 473.3 ng/µL. Extracted genomic
DNA from EG10 and TAP14 was then used for PCR amplification with the use of ITS fungal
primers. Into a 1.5 mL PCR tube, 21 µL of Bio-Rad master mix,1 µL ITSF, 1 µL ITSR, and 2 µL
of DNA was added for a total PCR volume of 25 µL. DNA concentrations were diluted using
1:10 and 1:100 dilutions for PCR amplification.
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Figure 3.2 TAP14-34A-2 Gel Electrophoresis
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Figure 3.3 TAP14-34A-2 DNA Sanger Sequencing Results
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Figure 3.4 NCBI nucleotide BLAST results for TAP14-34A-2
TAP14-34A-2 was sequenced using Sanger sequencing following purification using the
ITS4 region. The PCR product (1:100 diluted DNA) was sent to GeneWiz for purification and
yielded sequences from a chromatogram shown in Figure 3.3 that were then aligned using the
BLAST feature in NCBI for sequence similarity displayed in Figure 3.4. The TAP14 PCR
product was cleaned up using enzyme purification followed by chain-terminating PCR, size
separation by capillary gel electrophoresis, and sequence detection producing the output
chromatogram.
Due to time limitations, EG10-21E-2 could not be sent to GeneWiz for Sanger
sequencing due to the inability to amplify the ITS region through PCR amplification. Through
extensive literature searches, EG10-21E-2 would require primers specific to the translational
elongation factor region (TEF-1).4 Therefore, newly designed primers that target the TEF-1
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region would be needed to conduct PCR amplification and gel electrophoresis before sending to
GeneWiz for Sanger sequencing for EG10-21E-2.
3.4. Antimicrobial Assay of SPT1 & SPT2
EG10-21E-2 and TAP14-34A-2 MPLC fractions were screened against Candida albicans
and Candida auris (C. albicans MYA2876 and ATCC18804, C. auris) and the ESKAPE
pathogens. Extracts were prepared in 96-well plates containing the fraction concentrated in 100%
DMSO prepared at 10 mg/mL. Antimicrobial assays of EG10-21E-2 and TAP14-34A-2 were
used for detection of possible drug resistance in ESKAPE pathogens and assure susceptibility of
drugs for infections.5 EG10-21E-2-C showed bioactivity against C. albicans MYA 2876 and
ATCC18804 (IC50 =1.99 µM) and EG10-21E-2-G, H, and I showed bioactivity against the grampositive ESKAPE pathogen S. aureus (see appendix B for ESKAPE and Candida albicans
inhibition data). Pure compound SPT1 (prepared at 5 mg/mL in 100 µL DMSO in a 1 mL
Eppendorf tube) was submitted for a bioassay against RSV (respiratory syncytial virus). SPT1
(prepared at 10mM in 50 µL DMSO in a 1 mL Eppendorf tube) was also screened against
tuberculosis (TB). TAP14-34A-2-D, E, and F were bioactive against gram-positive ESKAPE
pathogens E. faecium (IC50 = 5.56 µM) and S. aureus (IC50 = 6.23 µM). For TAP14-34A-2, there
was no bioactivity against C. albicans and C. auris. The inhibitory activity of EG10-21E-2 and
TAP14-34A-2 and their secondary metabolites evaluated against various antimicrobial assays
demonstrated the ability to combat these multi-drug resistant pathogens for future drug
development.
3.5 Summary and Conclusions
TAP14-34A-2 and EG10-21E-2 were extracted for genomic DNA and used for molecular
identification. TAP14-34A-2 was sequenced and identified using Sanger sequencing and NCBI
36

nucleotide blast for sequence similarity. The amplified ITS4 region of TAP14 PCR samples were
sequenced using GeneWiz and subjected to NCBI Blast to verify sequence similarity and
identify the origins of the fungi. Sequences generated from the Sanger sequencing result were
put into the NCBI GenBank program for identification. TAP14-34A-2 was identified as
Aspergillus pseudodeflectus. Endophytic fungi isolated from mangroves revealed bioactive
natural products having many biological, chemical, and pharmaceutical impacts. The
identification of TAP14-34A-2 as Aspergillus pseudodeflectus supports that isolated bioactive
natural product sclerotiorin was derived from the fungi genus Aspergillus having been previously
isolated from Aspergillus terreus.
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4. General Experimental Procedures
MPLC was performed using Teledyne Isco single Combi Flash Rf 200i 12 and 40g
columns equipped with an evaporating light scattering detector (ELSD) and ultraviolet light
(UV). HPLC was performed on a Shimadzu LC-20A equipped with ELSD and UV detectors.
Normal phase HPLC was performed using a Phenomenex Silica Luna semipreparative (100 Å,
250 x 10 mm, 10 µm) column. LC/MS-MS/data were obtained from an Agilent 6540 LC/QToFMS with ESI detection using a Phenomenex Kinetex C18 (50 x 2.1 mm, 2.6 µm) column. 1D and
2D NMR data were recorded using the Inova 600 MHz NMR spectrometer. NMR data were
obtained in CDCl3 and CD3OD (if necessary). DNA concentrations and purities for molecular
identification of endophytic fungi were recorded using a ThermoScientific Nanodrop 1000
Spectrophotometer. PCR reactions for DNA amplification were run using an Applied Biosystems
MiniAmp Thermal Cycler. Gel electrophoresis for EG10-21E-2 and TAP14-34A-2 was obtained
from a gel box using 90V for 50 minutes following preparing a standard 1% agarose gel and then
loading PCR product onto wells.
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Appendices
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Appendix A: Experimental and Supplemental Data for Chapter 2
LCMS Chromatograms
HPLC Chromatograms
NMR Spectra for EG10-21E-2
NMR Spectra for TAP14-34A-2

Figure A1. LCMS chromatogram for EG10-21E-2-C-4 (SPT1): (+) mode: Calculated Mass :
422.3057. Solvent conditions for the LCMS QTOF included a gradient of LCMS grade
acetonitrile and water + 0.1% formic acid (FA).
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Figure A2. LCMS chromatogram for TAP14-34A-2-D-1 (SPT2): (+) MSMS [M+H]+: 391.1330.
Exact Mass: 390.1234 [M+]. Solvent conditions for the LCMS QTOF included a gradient of
LCMS grade acetonitrile and water + 0.1% formic acid (FA).

Figure A3. NP HPLC chromatogram for EG10-21E-2-C obtained using a Hex: EtOAc gradient
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Figure A4. 1H NMR spectrum (600 MHz, CDCl3) of EG10-21E-2-C-4 (SPT1)

Figure A5. 13C NMR spectrum (150 MHz, CDCl3) of EG10-21E-2-C-4 (SPT1)
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Figure A6. HSQC NMR spectrum (600 MHz, CDCl3) of EG10-21E-2-C-4 (SPT1)

Figure A7. COSY NMR spectrum (600 MHz, CDCl3) of EG10-21E-2-C-4 (SPT1)
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Figure A8. HMBC NMR spectrum (600 MHz, CDCl3) of EG10-21E-2-C-4 (SPT1)

Figure A9. NOESY NMR spectrum (600 MHz, CDCl3) of EG10-21E-2-C-4 (SPT1)
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Figure A10. NP HPLC chromatogram of TAP14-34A-2-D obtained using a Hex: EtOAc gradient

Figure A11. 1H NMR spectrum (600 MHz, CDCl3) of TAP14-34A-2-D-1 (SPT2)
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Figure A12. HSQC NMR spectrum (600 MHz, CDCl3) of TAP14-34A-2-D-1 (SPT2)

Figure A13. COSY NMR spectrum (600 MHz, CDCl3) of TAP14-34A-2-D-1 (SPT2)
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Figure A14. HMBC NMR spectrum (600 MHz, CDCl3) of TAP14-34A-2-D-1 (SPT2)

Figure A15. 13C NMR Spectrum (150 MHz, CDCl3) of TAP14-34A-2-D-1 (SPT2)
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Figure A16. NOESY NMR spectrum (600 MHz, CDCl3) of TAP14-34A-2-D-1 (SPT2)
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Appendix B: Experimental and Supplemental Data for Chapter 3
Nanodrop Results for EG10-21E-2
Nanodrop Results for TAP14-34A-2
Phylogenetic Tree of TAP14-34A-2
Candida albicans Bioassay Results
ESKAPE Bioassay Results

Figure B1. Nanodrop results for EG10-21E-2
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Figure B2. Nanodrop results for TAP14-34A-2

Figure B3. Phylogenetic tree of TAP14-34A-2
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Table B1. Candida albicans bioassay averages

IC50 value: 1.99 µM
Figure B4. Candida albicans bioassay results (SPT1)
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Figure B5. ESKAPE bioassay results (EG10-21E-2-HDAC)

Table B2. TAP14-34A-2 MPLC fractions’ inhibition against ESKAPE
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E. faecium IC50 value: 5.56 µM

S. aureus IC50 value: 6.23 µM

Figure B6. ESKAPE IC50 bioassay results (SPT2)
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